What is Akili Interactive?
Founded in 2011 and headquartered in Boston, Akili Interactive operates at the critical intersection of healthcare and digital entertainment. The company specializes in the development of FDA-cleared therapeutic software designed to treat cognitive conditions through immersive, game-based platforms. By leveraging proprietary algorithms that target specific neural systems, Akili provides a novel, non-pharmacological treatment modality. This innovative digital health model has attracted significant attention from both life sciences investors and technology-focused venture capital firms, positioning the company as a leader in the burgeoning field of prescription digital therapeutics.
How much funding has Akili Interactive raised?
Akili Interactive has raised a total of $296.4M across 6 funding rounds:
Series A
$8.5M
Private Equity
$30.5M
Series B
$42.4M
Series C
$55M
Debt
$50M
Series D
$110M
Series A (2012): $8.5M, investors not publicly disclosed
Private Equity (2016): $30.5M led by JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and PureTech Health
Series B (2016): $42.4M supported by Amgen Business Development and Merck Ventures BV
Series C (2018): $55M featuring Temasek, Brooklands Capital Strategies, Amgen Business Development, M Ventures, JAZZ Venture Partners, Baillie Gifford, and Canepa Advanced Healthcare Fund
Debt (2021): $50M backed by Silicon Valley Bank
Series D (2021): $110M with participation from Neuberger Berman Funds, Polaris Partners, Mirae Assets, New Leaf Venture Partners, and Shionogi & Co
Key Investors in Akili Interactive
Temasek
A global investment company headquartered in Singapore that acts as a generational investor with a long-term perspective on transformative technologies.
M Ventures
The strategic corporate venture capital arm of Merck, focusing on early-stage investments and company creation in high-impact scientific sectors.
Amgen Business Development
A division of the global biotechnology leader dedicated to advancing innovative therapies and supporting the development of sustainable healthcare solutions.
What's next for Akili Interactive?
Following its latest major strategic investment, Akili Interactive is well-positioned to scale its commercial operations and expand its therapeutic pipeline. The company's trajectory suggests a focus on deepening its B2B partnerships with healthcare providers while simultaneously refining its direct-to-consumer digital health offerings. As the regulatory landscape for software-as-a-medical-device (SaMD) continues to evolve, Akili is expected to leverage its robust capital base to accelerate clinical validation and market penetration, ultimately aiming to redefine standard-of-care protocols for cognitive health management.
See full Akili Interactive company page
